A detailed history of American Portfolios Advisors transactions in Genmab A/S stock. As of the latest transaction made, American Portfolios Advisors holds 3,335 shares of GMAB stock, worth $68,267. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,335
Holding current value
$68,267
% of portfolio
0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023

BUY
$31.52 - $373.61 $105,119 - $1.25 Million
3,335 New
3,335 $107 Million
Q2 2022

Mar 20, 2023

SELL
$26.83 - $38.57 $9,256 - $13,306
-345 Reduced 10.34%
2,990 $97.1 Million
Q1 2022

Mar 21, 2023

SELL
$30.95 - $39.68 $8,201 - $10,515
-265 Reduced 7.95%
3,070 $111 Million
Q4 2021

Mar 21, 2023

SELL
$35.87 - $47.12 $7,281 - $9,565
-203 Reduced 6.09%
3,132 $124 Million
Q3 2021

Mar 22, 2023

SELL
$41.55 - $48.72 $36,190 - $42,435
-871 Reduced 26.12%
2,464 $108 Million
Q2 2021

Mar 22, 2023

SELL
$32.88 - $44.57 $51,851 - $70,286
-1,577 Reduced 47.29%
1,758 $71.8 Million
Q1 2021

Mar 22, 2023

SELL
$30.92 - $44.4 $49,502 - $71,084
-1,601 Reduced 48.01%
1,734 $56.9 Million
Q4 2020

Mar 22, 2023

SELL
$33.66 - $40.76 $56,144 - $67,987
-1,668 Reduced 50.01%
1,667 $67.8 Million
Q3 2020

Mar 22, 2023

SELL
$33.07 - $38.68 $53,837 - $62,971
-1,628 Reduced 48.82%
1,707 $62.5 Million
Q2 2020

Mar 24, 2023

SELL
$20.05 - $33.89 $1,102 - $1,863
-55 Reduced 5.23%
996 $33.8 Million
Q1 2020

Mar 24, 2023

SELL
$17.15 - $25.22 $39,170 - $57,602
-2,284 Reduced 68.49%
1,051 $22.3 Million
Q4 2019

Mar 24, 2023

SELL
$18.88 - $24.14 $43,103 - $55,111
-2,283 Reduced 68.46%
1,052 $23.5 Million
Q3 2019

Mar 24, 2023

SELL
$18.0 - $21.38 $41,094 - $48,810
-2,283 Reduced 68.46%
1,052 $21.3 Million

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $13.5B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.